Exagen Inc. Reports Second Quarter 2026 Financial Results
EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY revenue guidance ($72M to $75M), record Q2 revenue and test volume growth, higher trailing-twelve-month ASP, and a narrowed adjusted EBITDA loss, alongside ending cash of about $25M.
Market read
A guidance raise with improved operating metrics can re-rate near-term expectations, but persistent losses mean the stock may remain sensitive to execution and cash burn.
What to watch
Investors may scrutinize whether the ASP and test-volume gains are sustainable and whether cash burn trends support the path to cash generation beyond the next few quarters.
Background
This is an SEC Form 8-K (Item 2.02) reporting Exagen’s Q2 2026 financial results and related corporate updates, including a full-year guidance increase.
Ticker impact
Exagen reported Q2 2026 results and raised full-year 2026 revenue guidance to $72 million to $75 million.
Likely supportive for shares on open, with follow-through dependent on whether investors focus on guidance range and cash burn trajectory.
The filing discloses multiple decision-relevant datapoints: record revenue and test volume, higher trailing-twelve-month ASP, narrowed adjusted EBITDA loss, and an explicit full-year revenue guidance raise.
Market effects
Autoimmune diagnostics peers may see read-across interest if investors treat AVISE CTD evidence generation and ASP expansion as demand-quality signals.
Limited, primarily affects US small-cap biotech/diagnostics sentiment rather than a specific region.
Low; the disclosure is company-specific with no stated international regulatory or reimbursement change.
Counterpoint
Despite guidance lift, the company still reports GAAP net losses and adjusted EBITDA remains negative, so the market may discount the improvement as incremental.
Key entities
- companyExagen Inc.
Nasdaq-listed autoimmune diagnostics provider reporting Q2 2026 results and updated FY 2026 revenue guidance.
- productAVISE CTD
Exagen’s flagship test referenced for volume growth and ASP expansion, plus clinical evidence generation.
